Hemogenyx Historical Cash Flow
| HEMO Stock | 343.40 20.90 6.48% |
Analysis of Hemogenyx Pharmaceuticals cash flow over time is an excellent tool to project Hemogenyx Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as End Period Cash Flow of 1.9 M or Stock Based Compensation of 231 as it is a great indicator of Hemogenyx Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Hemogenyx Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Hemogenyx Pharmaceuticals is a good buy for the upcoming year.
Hemogenyx |
About Hemogenyx Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Hemogenyx balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Hemogenyx's non-liquid assets can be easily converted into cash.
Hemogenyx Pharmaceuticals Cash Flow Chart
Add Fundamental
Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Hemogenyx Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Hemogenyx Pharmaceuticals PLC operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Hemogenyx Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Hemogenyx Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hemogenyx Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Hemogenyx Pharmaceuticals' Issuance Of Capital Stock is comparatively stable compared to the past year.
Hemogenyx Pharmaceuticals cash flow statement Correlations
Click cells to compare fundamentals
Hemogenyx Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Hemogenyx Pharmaceuticals cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (1.3M) | 1.3M | 5.0M | (4.3M) | (1.3M) | (1.2M) | |
| Free Cash Flow | (1.2M) | (2.0M) | (3.4M) | (3.3M) | (6.2M) | (5.9M) | |
| Other Cashflows From Financing Activities | (39.4K) | (433.0K) | (12.0M) | (110.1K) | (638.8K) | (670.7K) | |
| Capital Expenditures | 11.9K | 173.0K | 818.0K | 428.9K | 117.3K | 180.2K | |
| Total Cash From Operating Activities | (1.2M) | (1.8M) | (2.6M) | (2.9M) | (6.1M) | (5.8M) | |
| Net Income | (1.5M) | (2.1M) | (5.1M) | (4.0M) | (6.7M) | (6.4M) | |
| Total Cash From Financing Activities | (39.4K) | 3.2M | 8.8M | (110.1K) | 4.4M | 4.7M | |
| End Period Cash Flow | 498.7K | 1.8M | 6.8M | 2.5M | 1.2M | 1.9M | |
| Stock Based Compensation | 122.5K | 363.1K | 153.4K | 17.6K | 242.84 | 230.7 | |
| Change In Working Capital | (1.8K) | (56.5K) | 101.4K | 242.6K | (833.6K) | (791.9K) | |
| Begin Period Cash Flow | 1.8M | 498.7K | 1.8M | 6.8M | 2.5M | 2.0M | |
| Other Non Cash Items | 17.1K | 30.0K | 2.1M | 621.0K | 772.8K | 663.1K | |
| Change To Account Receivables | 16.1K | (21.4K) | (196.7K) | (2.1K) | 4.5K | 4.7K | |
| Other Cashflows From Investing Activities | 14.2K | 3.4K | 18.0K | 10.6K | 85.3K | 89.6K | |
| Investments | 2.3K | (169.7K) | (939.0K) | (420.3K) | (31.9K) | (33.5K) | |
| Net Borrowings | 1.2M | (39.4K) | 420.5K | (3.2M) | (2.9M) | (2.8M) | |
| Total Cashflows From Investing Activities | (20.2K) | 2.3K | (169.7K) | (939.0K) | (845.1K) | (802.8K) | |
| Depreciation | 94.7K | 106.8K | 126.3K | 195.2K | 645.7K | 678.0K | |
| Change To Netincome | 157.9K | 233.6K | 2.2M | 630.9K | 725.5K | 845.2K | |
| Change To Liabilities | 7.6K | (98.7K) | (17.9K) | (35.7K) | 298.1K | 0.0 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Hemogenyx Stock Analysis
When running Hemogenyx Pharmaceuticals' price analysis, check to measure Hemogenyx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemogenyx Pharmaceuticals is operating at the current time. Most of Hemogenyx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hemogenyx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemogenyx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hemogenyx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.